death or chronic RRT was 90 days (95% CI 14-166). One-year cumulative RRT-free survival was 26% in the ward, 36% in high dependency units and 48% in intensive care unit subgroups. Diabetes, gender and CKD at baseline did not affect RRT-free survival in the cohort being studied. A quarter of the cohort regained full renal function and 15% of survivors were on a chronic dialysis programme at 1 year. Conclusions: This study gives a comprehensive summary of renal outcomes and mortality after a single episode of AKI requiring RRT. The findings of the study confirm that dialysis-dependent AKI is associated with increased length of hospital stay, high mortality and loss of renal function long term, emphasizing the importance of recognition, classification and prevention of AKI.
placement therapy (RRT). A large meta-analysis estimated the global impact of AKI in 2013 to be close to 50 million patients [2] . Recent studies demonstrated that AKI increases mortality rates, morbidity, progression to chronic kidney disease (CKD) and length of hospital stay [3] [4] [5] [6] [7] . Even a small rise in serum creatinine has been recognised as an important prognostic factor for worse clinical outcomes [6] . Mortality is especially high in the critical care setting, with rates of up to 80% if RRT is required [8] . Of the surviving patients, 5-20% remain dialysis dependent at hospital discharge [5] .
Accurate identification of patients at risk of developing AKI warrant an unambiguous definition, to improve outcomes through better prevention strategies and therapeutic interventions. Since the introduction of the KDIGO AKI staging system in 2012 [1, 9] , a steady increase in observational studies and systematic reviews have been observed, suggesting that the lack of global nomenclature historically has resulted in an underestimation of the impact of AKI on morbidity, mortality, hospital stay and medical costs [2, 10, 11] .
The incidence of all-severity AKI in the UK is estimated to be as high as 620 per million population per year [12] . The most recent studies describing the impact of AKI on the National Health Service (NHS) in Scotland were conducted 10 years ago, prior to the introduction of the KDIGO guidelines for AKI. A Scotland-wide study performed in 2002 estimated the incidence of AKI requiring RRT to be 286 per million population [13] . An incidence of 252 per million population was estimated by the authors of a study conducted in the Grampian NHS board in 2003 [4] , which has a comparable population size and distribution as NHS Tayside.
This study was aimed at examining the incidence of AKI requiring RRT in the geographical region covered by NHS Tayside and describing the impact of RRT for AKI on the length of hospital stay, mortality and morbidity.
Methods
Design and Study Cohort NHS Tayside Board covers both rural and urban geographical areas in the east of Scotland, with a population estimate of 412,000 persons in 2012. Acute RRT services in the Tayside region of Scotland are limited to Ninewells Hospital in Dundee. Depending on the clinical condition and therapeutic needs of the patient, intermittent haemodialysis (HD) or sustained low-efficiency dialysis (SLED) is provided in the intensive care unit (ICU). HD treatments are provided in medical and surgical high dependency units (HDU), coronary care unit and the renal clinical inpatient unit, which will be referred to as 'ward' in this paper. All HD and SLED treatments are prescribed and supervised by members of the renal team and routinely recorded. All patients (>18 years of age) who received acute RRT in NHS Tayside between January 1, 2012 and December 31, 2012 were retrospectively selected for inclusion in the longitudinal cohort study.
Data Collection
Approval from the local data protection officer was obtained to collate data from electronic-and paper-based patient records. Patients entered the cohort on the first day of dialysis and were followed up for 1 year or until death (if earlier). Patients were excluded, if receiving chronic HD or peritoneal dialysis. Likely cause of AKI ascertained by a renal physician for all patients and cause of death as documented by the clinician for the non-survivors was recorded.
Definitions
Baseline characteristics such as age, sex, diabetic status and CKD status were collated. The following audit measures were defined in accordance with the Acute Kidney Injury guidelines published by the Renal Association [8] . Baseline creatinine was defined as a stable recent serum creatinine measurement within 3 months of the index admission date. If such measurement was not available, a measurement within 1 year of the index date was accepted. KDIGO AKI staging criteria were used to define the AKI stage at which RRT was initiated [1] . Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease formula [14] . Baseline eGFR ≥ 60 ml/min was considered to represent preserved renal function. CKD stages 3, 4 and 5 (ND) were defined as eGFR 30-59, 15-29 and <15 ml/min but not on dialysis, respectively [15] . Complete renal recovery was defined by a return of serum creatinine within 20% of baseline value. Partial renal recovery at 90 days and 1 year were defined as a stable return of serum creatinine to a value more than 20% above the baseline value, but without the requirement of chronic RRT [8] . RRT-free survival was defined as survival without requiring chronic RRT.
Statistical Analysis
For incidence calculations, a mid-point population estimate and median age in NHS Tayside were obtained from National Records of Scotland [16] . Incidence rate was defined as the number of disease onset divided by the sum of patient-time at risk. As this study dealt with a dynamic population (as patients may move in and out of NHS Tayside), the patient-time was equal to the average population multiplied by the follow-up time.
Descriptive statistics were used to summarise the renal function at baseline, discharge and during follow-up (90 days and 1 year after commencing RRT). Those patients lost to follow-up were excluded from analysis of outcome measures at 90 days and 1 year. Patients with missing data were excluded from analysis of the variable of interest only.
Chi-square test was used to compare categorical data such as community acquired AKI (CA-AKI) vs. hospital acquired AKI (HA-AKI), dialysis setting (ICU vs. HDU vs. ward) and death (yes vs. no) between patients with and without pre-existing CKD (acute on chronic renal failure (ACRF) vs. AKI). Chi-square test was performed to compare patients receiving RRT in ICU, HDU and the ward, between males and females, diabetics and non-diabetics, in AKI and ACRF groups and between patients receiving HD or SLED in ICU. RRT-free survival and time-until-event (death or RRT) analysis was performed using Kaplan-Meier plots. Cox-regression was used to examine relationship between age, sex, diabetes and CKD on survival. All statistical analyses were performed using SPSS version 21 (IBM, Armonk, N.Y., USA), and p < 0.05 was considered statistically significant.
Results
During the 12 months study period, 178 cases requiring HD for AKI were identified. Two cases were excluded because of incorrectly recorded patient information. Five patients were lost to follow-up at 90 days and 1 year, due to transfer to another health board after the acute phase of treatment.
The incidence of patients developing AKI that required RRT in NHS Tayside was calculated as 430 per million population per year. 
Characteristics of AKI Patients Requiring RRT

Initiation of Dialysis
Dialysis can be performed in ICU, HDU or the renal ward, depending on the disease severity. The majority (81%) of RRT was started in either ICU or HDU; 67 patients received RRT in ICU, of which 54 (81%) received SLED either as a single modality or in combination with HD. The remaining 13 patients (19%) in ICU received HD only. More patients who received their dialysis in ICU or HDU had preserved renal function prior to their admission as compared to the patients in ward (67 vs. 53 vs. 39% for ICU, HDU and ward, respectively) (χ 2 (2, n = 174) = 6.944, p = 0.03).
Causes of AKI
Prevention of AKI warrants insight into the aetiology of the disease. AKI in the study population was primarily caused by infection/sepsis syndrome (43%) or reduced renal perfusion due to volume depletion or hypotension (16%). A detailed overview of causes of AKI is presented in online supplementary table 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000447544).
In 37 cases (21% of total cohort), the use of medication interacting with the renovascular system contributed to the development of AKI (online suppl. fig. 1 and table 3 ). Two-thirds of these patients developed AKI in the community, 46% were on more than one interacting drug while developing AKI and 17 out of 37 patients (46%) were on inhibitors of the renin-angiotensin system. Intravenous contrast media used prior to the development of HA-AKI was identified in 11 cases. Non-steroidal antiinflammatory drugs, trimethoprim or metformin used prior to admission was associated with AKI in 12 cases.
Outcomes of AKI Requiring RRT
This study was aimed at describing the impact of RRT for AKI on the length of hospital stay, mortality and morbidity. The median length of hospital stay was 21 days (IQR 9-38). Of the 176 patients included in the study, 64 patients (36%) died in hospital and an additional 8% died within the first 90 days after the start of RRT. Total mortality after 1 year of follow-up was 54%. Further analysis of mortality data showed that 53% of the deaths within the first year were the result of infection/sepsis or cardiovascular causes (online suppl. table 2). In-hospital mortality rates for patients with AKI stage 1 or 2 at the time of RRT initiation were 49% compared to 29% for patients with AKI stage 3. Ninety day mortality for both groups was 57 and 36%, respectively. In-hospital mortality, 90-day mortality and 1 year mortality rates were higher among those that received dialysis in ICU or HDU when compared with the patients in ward ( fig. 1 ) . In-hospital mortality rates for the patients in ICU who received SLED alone or a combination of SLED and HD, were higher than for those that received HD only (SLED: 62%, HD + SLED: 25%, HD only: 39%, χ 2 (1, n = 176) = 8.36, p = 0.004).
Morbidity was defined as persistent loss of renal function, measured at 3 time points during follow-up. At discharge, only 30% of all patients regained full renal function and 7% (n = 13) remained dialysis dependent; 6 of these patients had CKD on admission. Of those that had a partial renal recovery on discharge (n = 47), 39% died within the first year of follow-up, 1 patient (2%) required chronic RRT.
At 1 year, 6% (n = 11) of the patient cohort (which equals 15% of the survivors) was on a chronic dialysis programme and 25% (n = 43) of all patients had a completely recovered renal function ( fig. 2 ) .
RRT-Free Survival
In practise, the ultimate goal of emergency dialysis during an acute illness is to regain full level of fitness and renal function long term. The RRT-free survival in the study cohort equals this and is visible in figure 3 a, which depicts the time from first session of RRT until death or chronic RRT in the study cohort. The median time from the start of RRT until death or chronic RRT was 90 days (95% CI 14-166), 6 patients died on the day RRT was initiated. Thirty-nine percent of the cohort survived 1 year without requiring RRT. Median RRTfree survival was 132 days (95% CI 0-291) in the AKI group, 76 days (95% CI 0-155) in the ACRF group (log rank testing not significant). Cumulative RRT-free survival at 90 days and 1 year did not differ for AKI and ACRF subgroups ( fig. 3b) .
Median survival was 58 days in the subgroup that was dialysed in the ward (95% CI 4-112) and 57 days in the HDU-subgroup (95% CI 0-139; fig. 3 c) . One-year cumu- Fig. 2 . Renal recovery at 1 year follow-up. After 1 year follow-up, 54% of patients had died and 6% was put on a chronic dialysis programme. One quarter of patients had a fully recovered renal function, whereas the renal function of 13% of patients had not returned to its baseline. n = 174. LTF = Lost to follow-up. Missing values, n = 2. 
Discussion
This study showed an incidence of AKI requiring RRT of 430 per million patients per year with an average length of hospital stay of 21 days per patient. In-hospital mortality was 36% and 1 year mortality 54%. In-hospital mortality was higher among those who received RRT in intensive care or higher care settings as compared to the ward setting, with the highest mortality of 62% for those receiving SLED in ICU. One-third of all patients had a completely recovered renal function on discharge and at 90 days post-RRT. At 1 year, only 25% of the patient cohort had maintained their complete renal recovery, and 6% were established on a chronic RRT programme.
The study data show a rise in the annual incidence of 50% as compared with the Scottish incidence estimate from 2003 [13] . This is in line with results of a large American retrospective cohort study performed in 2013 [11] , which reported an approximate 10% increase in incidence of AKI requiring RRT per annum since 2000. Interestingly, the incidence has climbed despite increased global effort to improve prevention and management of AKI of all levels of severity. Ageing populations of the developed countries [11, [17] [18] [19] may account for these increased rates due to an increase in prevalence of risk factors for the development of AKI such as cardiovascular disease, diabetes mellitus and CKD. One could also argue that the threshold to initiate RRT may have been lowered in recent years. However, our data suggest that there has been little change in local practice when starting patients on RRT, with a median age of 72 years in the study cohort, which is similar to that reported in the large Scottish cohort study in 2003 by Prescott et al. [13] .
To improve morbidity and mortality after AKI, it is paramount to recognise the severity of the disease impact and to identify risk factors leading to less than complete recovery of renal function, dialysis dependence or death. A wide array of potentially modifiable risk factors for the development of AKI has been identified [20] [21] [22] [23] . These include volume depletion/hypotensive state, surgery, sepsis/infection and use of contrast media and medication interacting with the renovascular system. Infection/ sepsis syndrome and extracellular fluid depletion were the 2 most common causes directly leading to AKI in this study. No differences in the cause of AKI between subgroups (CA-AK vs. HA-AKI, ACRF vs. AKI) were identified. AKI was caused by IV contrast in 11 patients (6%). A further 26 patients (15%) required RRT for AKI exacerbated by the use of antihypertensive medication, opiColor version available online oids or non-steroidal anti-inflammatory drugs, exacerbation of hyperkalaemia or acidosis (online suppl. table 3) . Timing of initiation of RRT has been a subject of debate; 2 recent publications randomised critically ill patients with AKI stage 2 or 3 to early initiation (within 6 h of documentation of AKI stage 3) or late initiation (after 72 h of oliguria or when severe laboratory abnormalities such as hyperkalaemia, uraemia or acidaemia developed) of RRT [24, 25] . Gaudry et al. [24] reported no significant difference in 60-day mortality between the early-strategy group and the delayed-strategy group, whereas Zarbock et al. [25] recorded reduced 90-day mortality, length of hospital stay and duration of RRT in the early initiation group. In our heterogeneous cohort of patients receiving RRT in an intensive care, and high dependency or ward setting 65% had AKI stage 3 when RRT was initiated ( table 1 ). As opposed to the survival advantage reported by Zarbock et al. [25] , 90-day mortality was 36% in AKI stage 3 group, as compared to 57% in the combined AKI stages 1 and 2 group. Due to the retrospective design of this study and relatively small study size, it was not powered to distinguish a significant difference in mortality between both groups. Life-threatening complications of rapid onset AKI stage 1 or 2 such as hyperkalaemia, acidaemia and fluid overload are well-known indications to start RRT before AKI stage 3 has developed, delaying RRT would be detrimental in these circumstances. This phenomenon might explain the reported in-hospital and 90-day mortality rates in the AKI 1 and 2 groups.
According to published reports, chronic RRT rates after admission for AKI vary widely; from 8 to 14% in mixed cohorts including patients with CKD and preserved renal function [26, 27] to 49% in a CKD cohort [28] . Even a small reduction of renal function after an episode of AKI has been found to have major long-term effects on the quality of life and health resources [7, 29] . Moreover, patients with an acute illness, severe enough to cause dialysis-dependent AKI are likely to lose significant muscle mass causing an overestimation of follow-up eGFR. Consistent with previous research, this study provides further evidence of the increased risk of incomplete renal recovery and chronic dialysis dependence up to 1 year after a single episode of AKI requiring RRT.
Small retrospective dataset analyses have previously been done to assess the incidence and outcomes of CA-AKI and HA-AKI. AKI of all severities is found to develop more often in the community than in hospital, with percentages of CA-AKI ranging between 67 [30] and 79% [31, 32] . In our RRT cohort, 53% patients developed AKI in the community. Age, length of hospital stay, recovery rates of renal function and mortality rates were equal in HA-AKI and CA-AKI. This contradicts the British retrospective analysis of renal outcomes post CA-AKI and HA-AKI published in 2014 [30] , where the length of hospital stay was significantly longer and inhospital mortality rates were higher in HA-AKI. A possible explanation for this discrepancy is that Wonnacott et al. [30] included AKI of all severities, with a high percentage of AKI stages 1 and 2.
Baseline co-morbidity influences decision making related to the intensity of treatment when dealing with an acutely unwell patient. A preserved baseline renal function was associated with dialysis in ICU, where pre-existing CKD was associated with dialysis in the ward. The mortality rate of patients who were dialysed in the ward rose considerably between discharge, 90 days and 1 year (6, 24 and 41%, respectively). An explanation for the rise in mortality within the first year potentially lies in the higher co-morbid state of this subgroup; CKD is widely recognised as being associated with increased all-cause mortality and kidney disease progression [33, 34] .
Eighty-one percent of acute dialysis treatments were initiated either in ICU or HDU, which demonstrates the disease severity of patients requiring acute dialysis. SLED, modality of choice in patients with haemodynamic instability [35] [36] [37] , was prescribed for 81% of patients in ICU. The majority of patients in ICU and HDU present with multi-organ failure, and their in-hospital mortality was statistically significant and higher than those for patients in the ward ( fig. 1 ) .
This study has several strengths. It used a heterogeneous and representative cohort from the NHS Tayside area, which centralises its RRT to one hospital with routine recording of all RRT provided. All AKI episodes were classified according to the KDIGO AKI staging system. Limitations include a relatively small cohort size and short duration of follow-up. Therefore, the potential confounding effects of diabetes and the presence of proteinuria in our subgroup analyses could not be established. Studies with a larger sample size, formal disease severity scoring and longer follow-up time are warranted to establish the longterm effects of AKI on progression towards RRT and death.
Conclusions
This observational study is the first British study to comprehensively characterise patients with AKI requiring RRT since the implementation of the AKI staging system in 2007. A significant rise in the annual incidence of AKI requiring RRT was demonstrated as compared to the Scottish estimate from 2003. Moreover, it was reported that within the first year of commencing RRT 73% of patients died or lost a significant proportion of renal function. Hereby increasing their mortality and risk of developing CKD. The study results emphasise the invaluable importance of early recognition, prevention and classification of AKI.
